Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Metastatic Prostate Cancer
share announcement

Advances in Metastatic Prostate Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 21 April 2025 | Viewed by 1998

Special Issue Editor

Dr. Orazio Caffo

E-Mail Website
Guest Editor
Department of Medical Oncology, Santa Chiara Hospital, 38112 Trento, Italy
Interests: prostate cancer; bladder cancer; renal cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last two decades, unprecedented improvements in the knowledge of the biology of advanced prostate cancer have led to dramatic changes in the therapeutic landscape of this disease.

The disease state, formerly known as hormone-refractory, has now been defined as castration-resistant according to the central role which is covered by androgen-receptor machinery in all disease states. This has led to the development and use of androgen-receptor signaling inhibitors (ARSIs) which produce improved survival outcomes in metastatic-castration-resistant prostate cancer (mCRPC) patients before or after docetaxel use. In recent years, docetaxel and ARSIs have been used in earlier disease states, such as non-metastatic CRPC or metastatic-castration-sensitive prostate cancer, reducing the proposed therapeutic options in the mCRPC setting.

More recently, the use of PARP inhibitors and Lu-PSMA has exploited new therapeutic targets, enhancing the available options in mCRPC. These strategies, which improve patients’ prognosis in late phases, are being used for testing in earlier disease states. Meanwhile, molecular imaging with new radiotracers provides more accurate disease pictures. In this renewed landscape, the knowledge of genomic profiling is limited by technical challenges due to the characteristics of available tissue samples, with increasing efforts being exerted to develop reliable and reproducible liquid biopsy-based analyses.  

This Special Issue, titled “Advances in Metastatic Prostate Cancer”, aims to highlight approaches which could improve the contemporary and future management and treatment of metastatic prostate cancer.

Dr. Orazio Caffo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • genomic profiling
  • therapeutic sequences
  • immunotherapy
  • chemotherapy
  • hormone-therapy
  • molecular imaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 5176 KiB  
Article
Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis
by Carlos S. Moreno, Cynthia L. Winham, Mehrdad Alemozaffar, Emma R. Klein, Ismaheel O. Lawal, Olayinka A. Abiodun-Ojo, Dattatraya Patil, Benjamin G. Barwick, Yijian Huang, David M. Schuster, Martin G. Sanda and Adeboye O. Osunkoya
Cancers 2023, 15(23), 5671; https://doi.org/10.3390/cancers15235671 - 30 Nov 2023
Cited by 3 | Viewed by 1591
Abstract
Prostate cancer is a highly heterogeneous disease and mortality is mainly due to metastases but the initial steps of metastasis have not been well characterized. We have performed integrative whole exome sequencing and transcriptome analysis of primary prostate tumor foci and corresponding lymph [...] Read more.
Prostate cancer is a highly heterogeneous disease and mortality is mainly due to metastases but the initial steps of metastasis have not been well characterized. We have performed integrative whole exome sequencing and transcriptome analysis of primary prostate tumor foci and corresponding lymph node metastases (LNM) from 43 patients enrolled in clinical trial. We present evidence that, while there are some cases of clonally independent primary tumor foci, 87% of primary tumor foci and metastases are descended from a common ancestor. We demonstrate that genes related to oxidative phosphorylation are upregulated in LNM and in African-American patients relative to White patients. We further show that mutations in TP53, FLT4, EYA1, NCOR2, CSMD3, and PCDH15 are enriched in prostate cancer metastases. These findings were validated in a meta-analysis of 3929 primary tumors and 2721 metastases and reveal a pattern of molecular alterations underlying the pathology of metastatic prostate cancer. We show that LNM contain multiple subclones that are already present in primary tumor foci. We observed enrichment of mutations in several genes including understudied genes such as EYA1, CSMD3, FLT4, NCOR2, and PCDH15 and found that mutations in EYA1 and CSMD3 are associated with a poor outcome in prostate cancer. Full article
(This article belongs to the Special Issue Advances in Metastatic Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop